BUSINESS & LABOR
UNITE FOR THE KNIGHT

About the Challenge

JOIN THE $1 BILLION CAMPAIGN TO STOP CANCER IN ITS TRACKS.

THE KNIGHT CANCER CHALLENGE.

Oregon Health & Science University is undertaking an unprecedented $1 billion campaign to find smarter, faster ways to detect cancer earlier when the disease is most curable. Nike co-founder Phil Knight and his wife, Penny, have pledged to donate $500 million to support the OHSU Knight Cancer Institute's ambitious plan — *if OHSU can raise an additional $500 million in gifts and pledges in two years.*

"Our goal is to use the molecular knowledge of what drives the growth of cancer to find it at its earliest, most curable stages. Our highest challenge is to do for early detection what Gleevec did for targeted treatments."

– *Brian Druker, M.D.*
Director, OHSU Knight Cancer Institute

We've changed the game before. We can do it again.

OHSU's Dr. Brian Druker proved it is possible to kill cancer cells while leaving healthy cells unharmed. This discovery of the cancer pill Gleevec®, the first targeted therapy of its kind, has revolutionized cancer research and treatment. Dr. Druker's goal is to use what we have learned about cancer through the development of drugs like Gleevec and apply this to the early detection of cancer.

With your support, we can take the next big step toward stopping cancer in our lifetime.

Here's how the Knight Cancer Institute will use a $1 billion investment to transform how doctors detect and treat cancer:

Bend the curve
Develop faster, smarter ways to detect and treat cancer – before it becomes deadly.

Beat the clock
Put unprecedented research resources behind this initiative so that it can make a significant impact in a decade.

Build the team
Assemble a collaborative, multidisciplinary team of cancer researchers, combining new recruits with top talent at OHSU to focus on improving early cancer detection, and fund their programs sufficiently to ensure they can devote their time to innovation.

Provide the tools
Make investments in imaging, diagnostics, clinical trial research, and computational biology to accelerate the pace of discovery and generate new breakthroughs.

GIVE TODAY:
uniteforthe knight.org